RSPO2
Overview
RSPO2 (R-Spondin 2) is a secreted Wnt pathway activator. Recurrent EIF3E-RSPO2 gene fusions were identified in colorectal cancer, providing an alternative mechanism of Wnt pathway activation distinct from APC mutations. RSPO fusion-positive tumors represent a novel molecular subset (~10% of CRC) and a potential target for antibody-based therapy.
Alterations observed in the corpus
- EIF3E(e1)-RSPO2(e2) gene fusion found in 3% of colorectal tumors; drives Wnt signalling activation; mutually exclusive with APC mutations PMID:22895193
- Recurrent RSPO2 fusions with overexpression observed in metastatic castration-resistant prostate cancer (150-case WGS/WES cohort); part of the WNT-pathway alterations (APC, CTNNB1, RNF43/ZNRF3) with predicted sensitivity to porcupine inhibitors and R-spondin antibodies. PMID:26000489
Cancer types (linked)
- COAD: EIF3E-RSPO2 fusion in 3% (WES, Genentech CRC cohort, 74 tumors); defines a novel Wnt-activated molecular subset PMID:22895193
Co-occurrence and mutual exclusivity
- Mutually exclusive with APC mutations; co-occurs with KRAS mutations in some samples PMID:22895193
Therapeutic relevance
- RSPO fusion-positive tumors represent attractive targets for antibody-based therapy directed against R-spondin proteins PMID:22895193
Open questions
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:26000489
This page was processed by crosslinker on 2026-05-14.